Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Andtbacka, Robert HI, Collichio, Frances A, Amatruda, Thomas, Senzer, Neil, Chesney, Jason, Delman, Keith, Spitler, Lynn, Puzanov, Igor, Agarwala, Sanjiv, Milhem, Mohammed, Harrington, Kevin, Middleton, Mark, Li, Ai, Shilkrut, Mark, Coffin, Robert, Kaufman, Howard
Format: Artigo
Language:Inglês
Published: BioMed Central 2014
Subjects:
Poster Presentation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4292568/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-2-S3-P263
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items